Anixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines for critical unmet needs in oncology. The company's therapeutics program focuses on liraltagene autoleucel ("lira-cel"), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell ("CAR-T") technology. This therapy is initially focused on treating ovarian cancer and is being developed by its subsidiary, Certainty Therapeutics, Inc. ("Certainty"). Anixa's vaccine programs include a vaccine against breast cancer, a vaccine against ovarian cancer, and a vaccine discovery program. This discovery program uses the same mechanism as the breast and ovarian cancer vaccines to develop additional cancer vaccines for intractable cancers, including high incidence malignancies in lung, colon, and prostate. Certainty, Anixa's subsidiary, develops immunotherapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license from The Wistar Institute ("Wistar") for intellectual property related to Wistar's chimeric endocrine receptor targeted therapy technology. While the initial focus is on ovarian cancer, the company may also pursue applications of this technology for other solid tumors. The license agreement requires Certainty to make cash and equity payments to Wistar upon achieving specific development milestones. Certainty initially issued Wistar shares of its common stock equal to five percent (5%) of Certainty's common stock. Due to company funding, Wistar's equity stake in Certainty was 4.1% as of October 31, 2025. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. ("Moffitt"), has started human clinical testing of lira-cel for ovarian cancer.